Accent Therapeutics is leading the translation of RNA-modifying protein(RMP)biology into promising new precision therapies for cancer.
Aquinnah Pharmaceuticals is developing small molecule therapeutics targeting persistent stress granules for the treatment of neurodegenerative disease.
Capsida Therapeutics is creating a new class of targeted gene therapies for both CNS and non-CNS disorders.
Caraway Therapeutics is developing novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy.
DG Medicines is employing a novel drug discovery platform to identify therapeutics for targeted protein degradation.
EndLyz Therapeutics is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias.
FireCyte is an emerging biotechnology company developing novel treatment strategies focused on the role of microglia and neuroinflammation in progressive neurodegenerative diseases of the eye.
Jnana Therapeutics is building the first drug discovery platform dedicated to the solute carrier family of transporters.
Nitrase Therapeutics is developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases.
PACT is developing personalized adoptive cell therapies based on neoantigen-targeted T cells against cancer.
Palleon Pharmaceuticals is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
Quanta Therapeutics is pioneering allosteric modulation to control RAS signaling for inhibition of the full scope of RAS-driven cancer types.
Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human disease.
Ribon Therapeutics is discovering first-in-class small molecule inhibitors to block cancer cells' ability to survive under stress.
Stemson Therapeutics is developing a novel treatment for hair loss, using iPS cells to grow new Dermal Papilla and generate hair follicles de novo.
Chemoproteomics Stealth NewCo is developing activity-dependent protein ligation technology for quantitative in-cell profiling.
Drug Delivery Stealth Newco is developing a synthetic drug carrier platform for subcutaneous nanotherapy.
Immunology Stealth NewCo is harnessing natural mechanisms for tolerance induction to transform outcomes in autoimmunity.
IPO, NASDAQ: ALEC
Acquired by Gilead
Acquired by CSL Behring
IPO, NASDAQ: CRBU
Acquired by Locust Walk Acquisition Corp (SPAC merger), NASDAQ: EFTR
IPO, NASDAQ: XCUR
IPO, NASDAQ: KALA
Acquired by Zymergen
IPO, NASDAQ: MORF
Acquired by Lilly
Acquired by Amgen
Acquired by Sanofi
Acquired by Gilead